Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer

Immune checkpoint blockade is promising for treating non-small-cell lung cancer (NSCLC). We used multipanel markers to predict the response to immune checkpoint inhibitors (ICIs) by characterizing gene expression signatures or individual genes in patients who showed durable clinical benefit to ICIs....

Descripción completa

Detalles Bibliográficos
Autores principales: Hwang, Sohyun, Kwon, Ah-Young, Jeong, Ju-Yeon, Kim, Sewha, Kang, Haeyoun, Park, Joonsuk, Kim, Joo-Hang, Han, Ok Jin, Lim, Sun Min, An, Hee Jung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971301/
https://www.ncbi.nlm.nih.gov/pubmed/31959763
http://dx.doi.org/10.1038/s41598-019-57218-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971301/
https://www.ncbi.nlm.nih.gov/pubmed/31959763
http://dx.doi.org/10.1038/s41598-019-57218-9

Ejemplares similares